首页 | 本学科首页   官方微博 | 高级检索  
检索        

宫颈上皮癌变过程中bcl-2、c-erbB2和p53蛋白的表达
作者姓名:Tang ZH  Cai QF  Ye XA
作者单位:1. 莆田学院基础医学部,病理学教研室,福建,莆田,351100
2. 莆田学院附属第二医院病理科,福建,莆田,351100
3. 邵武市立医院病理科,福建,邵武,354000
摘    要:背景与目的:宫颈上皮癌变分子生物学方面的研究报道较少,本研究拟探讨抗凋亡基因bcl-2、癌基因c-erbB2和抑癌基因p53表达在宫颈上皮癌发生发展中的意义。方法:应用免疫组化SP法检测48例宫颈鳞癌、42例宫颈上皮内瘤样病变(cervicalintraepithelialneoplasia,CIN)和20例正常宫颈组织中bcl-2、c-erbB2和p53蛋白的表达情况。结果:bcl-2、c-erbB2和p53在宫颈鳞癌、CIN和正常宫颈组织中阳性率分别为72.9%(35/48)、60.4%(29/48)、58.3%(28/48);61.9%(26/42)、38.1%(16/42)、26.2%(11/42);20.0%(4/20)、0.0%(0/20)、0.0%(0/20)。bcl-2在鳞癌、CIN中的表达与正常组织相比差异有显著性(P<0.001),而鳞癌组与CIN组之间的差异无显著性(P>0.05);c-erbB2和p53在鳞癌、CIN与正常组织中的表达有显著性差异(P<0.05);bcl-2、c-erbB2和p53在CIN3组与CIN和CIN2组相比差异有显著性(P<0.05)。bcl-2和p53表达与组织学类型、病理分级及临床分期有关(P<0.05)。bcl-2的表达随病理分级升高和临床分期进展而降低,而与淋巴结转移无关(P>0.05);p53表达结果与之相反;c-erbB2表达与组织学类型、病理分级、临床分期和淋巴结转移无关(P>0.05)。结论:在宫颈上皮癌变过程中,bcl-2过表达是宫颈癌发生的早期事件;c-erbB2过表达是细胞恶性变的标

关 键 词:宫颈上皮癌  bcl-2蛋白  c-erbB2蛋白  p53蛋白  抗凋亡基因  基因表达
文章编号:1000-467X(2003)10-1057-05
修稿时间:2002年11月27

Expression of bcl-2, c-erbB2, and p53 protein in cervical epithelial carcinogenesis
Tang ZH,Cai QF,Ye XA.Expression of bcl-2, c-erbB2, and p53 protein in cervical epithelial carcinogenesis[J].Chinese Journal of Cancer,2003,22(10):1057-1061.
Authors:Tang Zhong-Hui  Cai Qing-Fa  Ye Xing-An
Institution:Department of Pathology, Faculty of Preclinical Medicine, Putian College, Putian, Fujian, 351100, PR China. tzh6409@peoplemail.com.cn
Abstract:BACKGROUND&OBJECTIVE: Less research of molecular biology have been reported on cervical carcinogenesis. So the authors designed this study to evaluate the expression and clinical significance of antiapoptosis gene bcl 2, oncogene c erbB2, and tumor suppressor gene p53 in the progression of this kind of cancer. METHODS: Using S P immunohistochemical technique, the authors examined the expression of bcl 2, c erbB2, and p53 in 48 squamous cell carcinoma of the cervix, 42 cervical intraepithelial neoplasia(CIN),and 20 normal cervical tissues. RESULTS: The expression rates of bcl 2, c erbB2, and p53 were 72.9%(35/48),60.4%(29/48), and 58.3%(28/48) in carcinomas,61.9%(26/42),38.1%(16/42) ,and 26.2%(11/42) in CIN,20.0%(4/20),0.0%(0/20) ,and 0.0%(0/20) in normal cervices, respectively. The overexpression of bcl 2 protein in carcinomas and in CIN was remarkably higher than that in normal cervices(P< 0.01), and the difference between carcinomas and CIN was not significant(P>0.05). There were significant differences for c erbB2 and p53 between carcinomas and CIN and normal cervices, respectively(P< 0.05). There were significant differences for bcl 2,c erbB2, and p53 between CIN3 and CIN1 2, respectively(P< 0.05). Expression of bcl 2 and p53 were correlated with histological type, tumor grades, and clinical stages (P< 0.05). Expression of bcl 2 was lower keratinized than nonkeratinized and was lower as tumor grades and clinical stages increased(P< 0.05) .It was not associated with lymph node metastasis(P >0.05). However, the expression of p53 was contrary with bcl 2. Expression of c erbB2 was not associated with histological type, tumor grades, clinical stages, and lymph node metastasis(P >0.05). CONCLUSION: In cervical carcinogenesis, the overexpression of bcl 2 protein may be activated in the early stage of pathogenesis of cervical carcinoma. Expression of c erbB2 was the singal of cell malignant change. Expression of p53 was associated with the pathogenesis and development of cervical carcinoma.
Keywords:Cervical carcinoma  Immunohistochemistry  bcl-2 protein  c-erbB2 protein  p53 protein
本文献已被 CNKI 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号